Multiparametric Prostate MRI: PI-RADS V.2
|
|
|
- Rosaline Lynch
- 6 years ago
- Views:
Transcription
1 Multiparametric Prostate MRI: PI-RADS V.2 Katarzyna J. Macura, MD, PhD, FACR, FSCBTMR The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD SCBT MR 201 1
2 Objectives Discuss PI-RADS v2 Anatomical localization of abnormalities on multiparametric MRI (mpmri) of the prostate 36 prostate sectors Scoring imaging findings on T2WI, -ADC, DCE MRI Review PI-RADS v2 assessment categories
3 Prostate Sectors (36) Anatomy Laterality: Right R / Left L Superior to Inferior: Seminal Vesicle Base Mid Apex Urethra Zones: Anterior fibromuscular Stroma (AS) Transition Zone (TZ) Central Zone (CZ) Peripheral Zone (PZ) Additional modifiers: Anterior (a), Posterior (p), Lateral (l), Medial (m)
4 Prostate Sectors (36) Anatomy RSV LSV RB AS LB AS RB TZa LB TZa RB TZp LB TZp RB PZa LB PZa RB PZpl LB PZpl RB CZ LB CZ RM AS LM AS RM TZa LM TZa RM TZp LM TZp RM PZa LM PZa RM PZpl LM PZpl RM PZpm LM PZpm RX AS LX AS RX TZa LX TZa RX TZp LX TZp RX PZa LX PZa RX PZpl LX PZpl RX PZpm LX PZpm US
5 PI-RADS Peripheral Zone T2WI Peripheral Zone (PZ) 1 Uniformly hyperintense (normal) 2 Linear, wedge-shaped, or diffuse mild hypointensity, usually indistinct margin 3 Non-circumscribed, rounded, mild hypointensity Circumscribed, homogenous moderate hypointense focus/mass confined to prostate and <1. cm in greatest dimension Same as but 1.cm in greatest dimension or
6 PI-RADS Peripheral Zone T2WI Peripheral Zone (PZ) 1 Uniformly hyperintense (normal) 2 Linear, wedge-shaped, or diffuse mild hypointensity, usually indistinct margin 3 Non-circumscribed, rounded, mild hypointensity Circumscribed, homogenous moderate hypointense focus/mass confined to prostate and <1. cm in greatest dimension Same as but 1.cm in greatest dimension or
7 PI-RADS Peripheral Zone T2WI Peripheral Zone (PZ) 1 Uniformly hyperintense (normal) 2 Linear, wedge-shaped, or diffuse mild hypointensity, usually indistinct margin 3 Non-circumscribed, rounded, mild hypointensity Circumscribed, homogenous moderate hypointense focus/mass confined to prostate and <1. cm in greatest dimension Same as but 1.cm in greatest dimension or
8 PI-RADS Peripheral Zone T2WI Peripheral Zone (PZ) 1 Uniformly hyperintense (normal) 2 Linear, wedge-shaped, or diffuse mild hypointensity, usually indistinct margin 3 Non-circumscribed, rounded, mild hypointensity Circumscribed, homogenous moderate hypointense focus/mass confined to prostate and <1. cm in greatest dimension Same as but 1.cm in greatest dimension or
9 PI-RADS Peripheral Zone T2WI Peripheral Zone (PZ) 1 Uniformly hyperintense (normal) 2 Linear, wedge-shaped, or diffuse mild hypointensity, usually indistinct margin 3 Non-circumscribed, rounded, mild hypointensity Circumscribed, homogenous moderate hypointense focus/mass confined to prostate and <1. cm in greatest dimension Same as but 1.cm in greatest dimension or
10 PI-RADS Transition Zone T2WI Transition Zone (TZ) Homogeneous intermediate signal intensity (normal) Circumscribed hypointense or heterogeneous encapsulated nodule(s) (BPH) Heterogeneous signal intensity with obscured margins Non-circumscribed, homogeneous, moderately hypointense, and <1. cm in greatest dimension Same as, but 1.cm in greatest dimension or
11 PI-RADS Transition Zone T2WI Transition Zone (TZ) Homogeneous intermediate signal intensity (normal) Circumscribed hypointense or heterogeneous encapsulated nodule(s) (BPH) Heterogeneous signal intensity with obscured margins Non-circumscribed, homogeneous, moderately hypointense, and <1. cm in greatest dimension Same as, but 1.cm in greatest dimension or
12 PI-RADS Transition Zone T2WI Transition Zone (TZ) Homogeneous intermediate signal intensity (normal) Circumscribed hypointense or heterogeneous encapsulated nodule(s) (BPH) Heterogeneous signal intensity with obscured margins Non-circumscribed, homogeneous, moderately hypointense, and <1. cm in greatest dimension Same as, but 1.cm in greatest dimension or
13 PI-RADS Transition Zone T2WI Transition Zone (TZ) Homogeneous intermediate signal intensity (normal) Circumscribed hypointense or heterogeneous encapsulated nodule(s) (BPH) Heterogeneous signal intensity with obscured margins Non-circumscribed, homogeneous, moderately hypointense, and <1. cm in greatest dimension Same as, but 1.cm in greatest dimension or
14 PI-RADS Transition Zone T2WI Transition Zone (TZ) Homogeneous intermediate signal intensity (normal) Circumscribed hypointense or heterogeneous encapsulated nodule(s) (BPH) Heterogeneous signal intensity with obscured margins Non-circumscribed, homogeneous, moderately hypointense, and <1. cm in greatest dimension Same as, but 1.cm in greatest dimension or
15 PI-RADS Peripheral Zone 1 Peripheral Zone (PZ) No abnormality (normal) on ADC or high b-value 2 Indistinct mildy hypointense on ADC 3 Focal mildy hypointense on ADC and isointense/mildly hyperintense on high b-value Focal moderately hypointense on ADC and markedly hyperintense on high b-value ; <1.cm on axial Same as but 1.cm in greatest dimension or 1
16 PI-RADS Peripheral Zone 1 Peripheral Zone (PZ) No abnormality (normal) on ADC or high b-value 2 Indistinct mildy hypointense on ADC 3 Focal mildy hypointense on ADC and isointense/mildly hyperintense on high b-value Focal moderately hypointense on ADC and markedly hyperintense on high b-value ; <1.cm on axial Same as but 1.cm in greatest dimension or 16
17 PI-RADS Peripheral Zone 1 Peripheral Zone (PZ) No abnormality (normal) on ADC or high b-value 2 Indistinct mildy hypointense on ADC 3 Focal mildy hypointense on ADC and isointense/mildly hyperintense on high b-value Focal moderately hypointense on ADC and markedly hyperintense on high b-value ; <1.cm on axial Same as but 1.cm in greatest dimension or 17
18 PI-RADS Peripheral Zone 1 Peripheral Zone (PZ) No abnormality (normal) on ADC or high b-value 2 Indistinct mildy hypointense on ADC 3 Focal mildy hypointense on ADC and isointense/mildly hyperintense on high b-value Focal moderately hypointense on ADC and markedly hyperintense on high b-value ; <1.cm on axial Same as but 1.cm in greatest dimension or 18
19 PI-RADS Peripheral Zone 1 Peripheral Zone (PZ) No abnormality (normal) on ADC or high b-value 2 Indistinct mildy hypointense on ADC 3 Focal mildy hypointense on ADC and isointense/mildly hyperintense on high b-value Focal moderately hypointense on ADC and markedly hyperintense on high b-value ; <1.cm on axial Same as but 1.cm in greatest dimension or 19
20 PI-RADS Transition Zone 1 Transition Zone (TZ) No abnormality (normal) on ADC or high b-value 2 Hypointense within a BPH nodule on ADC 3 Focal mildly hypointense on ADC and isointense/mildly hyperintense on high b-value Focal markedly hypointense on ADC and markedly hyperintense on high b-value ; <1.cm on axial Same as but 1.cm in greatest dimension or 20
21 PI-RADS Transition Zone 1 Transition Zone (TZ) No abnormality (normal) on ADC or high b-value 2 Hypointense within a BPH nodule on ADC 3 Focal mildly hypointense on ADC and isointense/mildly hyperintense on high b-value Focal markedly hypointense on ADC and markedly hyperintense on high b-value ; <1.cm on axial Same as but 1.cm in greatest dimension or 21
22 PI-RADS Transition Zone 1 Transition Zone (TZ) No abnormality (normal) on ADC or high b-value 2 Hypointense within a BPH nodule on ADC 3 Focal mildly hypointense on ADC and isointense/mildly hyperintense on high b-value Focal markedly hypointense on ADC and markedly hyperintense on high b-value ; <1.cm on axial Same as but 1.cm in greatest dimension or 22
23 PI-RADS Transition Zone 1 Transition Zone (TZ) No abnormality (normal) on ADC or high b-value 2 Hypointense within a BPH nodule on ADC 3 Focal mildly hypointense on ADC and isointense/mildly hyperintense on high b-value Focal markedly hypointense on ADC and markedly hyperintense on high b-value ; <1.cm on axial Same as but 1.cm in greatest dimension or 23
24 PI-RADS Transition Zone 1 Transition Zone (TZ) No abnormality (normal) on ADC or high b-value 2 Hypointense within a BPH nodule on ADC 3 Focal mildly hypointense on ADC and isointense/mildly hyperintense on high b-value Focal markedly hypointense on ADC and markedly hyperintense on high b-value ; <1.cm on axial Same as but 1.cm in greatest dimension or 2
25 DCE: Positive / Negative Positive DCE Negative DCE Focal, early enhancement corresponding to a focal peripheral zone or transition zone lesion on T2 and/or MRI Lack of early enhancement Diffuse enhancement not corresponding to a focal lesion on T2 and/or MRI Focal enhancement corresponding to a BPH lesion
26 PI-RADS DCE PZ DCE Status Positive (+) Negative (-) PZ / TZ Enhancement Focal, earlier or contemporaneous with enhancement of adjacent normal prostatic tissues, and corresponding to a suspicious finding on T2WI and/or No early enhancement, or; diffuse enhancement so that margins do not correspond to a finding on T2WI and/or, or; focal enhancement corresponding to a lesion demonstrating features of BPH on T2WI
27 PI-RADS DCE TZ DCE Status Positive (+) Negative (-) PZ / TZ Enhancement Focal, earlier or contemporaneous with enhancement of adjacent normal prostatic tissues, and corresponding to a suspicious finding on T2WI and/or No early enhancement, or; diffuse enhancement so that margins do not correspond to a finding on T2WI and/or, or; focal enhancement corresponding to a lesion demonstrating features of BPH on T2WI
28 PI-RADS DCE DCE Status Positive (+) Negative (-) PZ / TZ Enhancement Focal, earlier or contemporaneous with enhancement of adjacent normal prostatic tissues, and corresponding to a suspicious finding on T2WI and/or No early enhancement, or; diffuse enhancement so that margins do not correspond to a finding on T2WI and/or, or; focal enhancement corresponding to a lesion demonstrating features of BPH on T2WI
29 PI-RADS v2 Overall Assessment Likelihood of the presence of clinically significant cancer 1 Very low clinically significant cancer highly unlikely 2 Low clinically significant cancer is unlikely 3 Intermediate clinically significant cancer is equivocal High clinically significant cancer is likely Very high clinically significant cancer is highly likely
30 Peripheral Zone -ADC Abnormality location PI-RADS v2 Assessment Category Transition Zone T2WI 1 PI-RADS PI-RADS 2 DCE - PI-RADS PI-RADS PI-RADS
31 Overall PI-RADS v2 Assessment T2W DCE PIRADS Category 1 Any Any 1 2 Any Any 2 3 Any Any Any Any Any
32 Overall PI-RADS v2 Assessment Peripheral Zone (PZ) Nodule 10 mm T2W DCE PIRADS Category 1 Any Any 1 2 Any Any 2 3 Any Any Any Any Any
33 Overall PI-RADS v2 Assessment Peripheral Zone (PZ) Nodule 10 mm T2W DCE PIRADS Category 1 Any Any 1 2 Any Any 2 3 Any Any Any Any Any
34 Thank you!
1 Uniform hyperintense signal intensity (normal). 2 Linear (arrow), wedge-shaped, or diffuse mild hypointensity, usually indistinct margin.
Figure 3 PI-RADS assessment for peripheral zone on T2-weighted imaging. 1 Uniform hyperintense signal intensity (normal). 2 Linear (arrow), wedge-shaped, or diffuse mild hypointensity, usually indistinct
PI-RADS V2 IN PRACTICE A PICTORIAL REVIEW
PI-RADS V2 IN PRACTICE A PICTORIAL REVIEW KP Murphy, A Walsh, C Donagh, R Aljurayyan, AC Harris, SD Chang Department of Abdominal and GU Radiology, Vancouver General Hospital & University of British Columbia,
Interac(ve Experience with Prostate Imaging Repor(ng and Data System Version 2 (PI-RADS v2)
Interac(ve Experience with Prostate Imaging Repor(ng and Data System Version 2 (PI-RADS v2) E Hassanzadeh 1,2, MD; E Velez 3, BS; F M Fennessy 1,4, MD, PhD; R M Dunne 1,2, MBBCh; M G Harisinghani 1,5,
HHS Public Access Author manuscript Abdom Radiol (NY). Author manuscript; available in PMC 2017 January 19.
Prostate Imaging Reporting and Data System Version 2 (PI- RADS v2): A pictorial review Elmira Hassanzadeh, MD 1, Daniel I Glazer, MD 1, Ruth M Dunne, MD 1, Fiona M Fennessy, MD, PHD 2, Mukesh G Harisinghani,
Standards for MRI reporting the evolution to PI-RADS v 2.0
Review Article Standards for MRI reporting the evolution to PI-RADS v 2.0 Michael Spektor, Mahan Mathur, Jeffrey C. Weinreb Department of Radiology and Biomedical Imaging, Yale New Haven Hospital, USA
Optimizing Implementation of Prostate MRI. Andrei S Purysko, M.D. Section of Abdominal Imaging & Nuclear Radiology Department
Optimizing Implementation of Prostate MRI Andrei S Purysko, M.D. Section of Abdominal Imaging & Nuclear Radiology Department Objectives To review the basic components of a state-of-the-art mpmri of the
Localized at a focus, central point or locus. Localized finding distinct from neighboring tissues, not a threedimensional
LEXICON ABNORMALITY Focal abnormality Focus Index Lesion Lesion Localized at a focus, central point or locus Localized finding distinct from neighboring tissues, not a threedimensional space occupying
11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.
Multi-parametric MRI of Prostate Diagnosis and Treatment Planning Temel Tirkes, M.D. Associate Professor of Radiology Director, Genitourinary Radiology Indiana University School of Medicine Department
PI-RADS version 2 - what we need to know
PI-RADS version 2 - what we need to know Poster No.: C-1846 Congress: ECR 2017 Type: Educational Exhibit Authors: I. Abreu, D. Roriz, A. P. Pissarra, Â. Moreira, C. B. Marques, 1 1 2 1 1 1 1 2 F. Caseiro
Prostate Cancer Imaging: most common pitfalls in multiparametric Magnetic Resonance
Prostate Cancer Imaging: most common pitfalls in multiparametric Magnetic Resonance Poster No.: C-0698 Congress: ECR 2017 Type: Educational Exhibit Authors: L. Basso, M. Baglietto, S. Migone, V. Prono,
I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.
Prostate t Cancer MR Report Disclosure Information Vikas Kundra, M.D, Ph.D. I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a g product
Prostate Cancer DFP Case of the Week
Prostate Cancer DFP Case of the Week Antonio C. Westphalen, MD PhD Clinical Prostate MR Imaging Program, Director Associate Professor of Radiology and Urology University of California, San Francisco Case
PI-RADS[1_TD$DIF] Prostate Imaging [30_TD$DIF] Reporting and Data System:2015, Version 2
![PI-RADS[1_TD$DIF] Prostate Imaging [30_TD$DIF] Reporting and Data System:2015, Version 2](/thumbs/76/73508212.jpg "PI-RADS[1_TD$DIF] Prostate Imaging [30_TD$DIF] Reporting and Data System:2015, Version 2")
EUROPEAN UROLOGY 69 (2016) 16 40 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Jelle O. Barentsz, Jeffrey C. Weinreb, Sadhna
Prostate MRI: Not So Difficult. Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX
Prostate MRI: Not So Difficult Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX What is the biggest barrier to your practice incorporating prostate MRI? 1) I don t know how to read the cases 2) I don
Prostate Cancer MRI. Accurate Diagnosis and Treatment. PSA to Prostate MRI. for patients and curious doctors
6 Prostate Cancer MRI Accurate Diagnosis and Treatment PSA to Prostate MRI for patients and curious doctors Samuel Aronson, M.D. Vincent Pelsser, M.D. Franck Bladou, M.D. Armen Aprikian, M.D. & Marc Emberton,
Improved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template
Improved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template Abstract #17-130 ACR Annual Meeting 2017 Presenting Author: Whitney
Prostate MRI. Overview. Introduction 2/20/2015. Prostate cancer is most frequently diagnosed noncutaneous cancer in males (25%)
Prostate MRI John Bell, MD Introduction Prostate Cancer Screening Staging Anatomy Prostate MRI overview Functional MRI Multiparametric Approach Indications Example Cases Overview Introduction Prostate
Essentials for establishing a successful MR-US fusion biopsy program
Essentials for establishing a successful MR-US fusion biopsy program Karthik M. Sundaram, M.D., Ph.D. Elizabeth Craig, M.D. - Instructor of Radiology and Radiological Sciences Lori Deitte, M.D. - Professor
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
PROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging
PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role
PI-RADS v2.1 PI-RADS. Prostate Imaging Reporting Version 2.1. American College of Radiology 2019 i PI-RADSv2.1
PI-RADS Prostate Imaging Reporting and Data System 2019 Version 2.1 American College of Radiology 2019 i PI-RADSv2.1 PI-RADS Prostate Imaging Reporting and Data System 2019 Version 2.1 American College
Prostate MRI based on PI-RADS version 2: how we review and report
Steiger and Thoeny Cancer Imaging (2016) 16:9 DOI 10.1186/s40644-016-0068-2 REVIEW Prostate MRI based on PI-RADS version 2: how we review and report Philipp Steiger 1,2* and Harriet C. Thoeny 1,2 Open
OASIS 1.2T: MULTIPARAMETRIC MRI OF PROSTATE CANCER
OASIS 1.2T: MULTIPARAMETRIC MRI OF PROSTATE CANCER By Dr. John Feller, MD, Radiologist Desert Medical Imaging, Palm Springs, CA MRI is clinically accepted as the best imaging modality for displaying anatomical
Prostate Imaging Reporting and Data System (PI-RADS), Version 2: A Critical Look
Genitourinary Imaging Opinion Rosenkrantz et al. ritical Look at Prostate Imaging Reporting and Data System, Version 2 Genitourinary Imaging Opinion FOUS ON: ndrew. Rosenkrantz 1 ytekin Oto 2 aris Turkbey
Current Clinical Practice. MR Imaging Evaluations. MRI Anatomic Review. Imaging to Address Clinical Challenges. Prostate MR
BETH ISRAEL DEACONESS MEDICAL CENTER Prostate MR Neil M. Rofsky, MD Harvard Medical School Current Clinical Practice DIGITAL RECTAL EXAMINATION PSA ( ~ 20% False negative) BIOPSY (18-25% False negative)
Problems: TRUS Bx. Clinical questions in PCa. Objectives. Jelle Barentsz. Prostate MR Center of Excellence.
Multi-parametric MR imaging in Problems: TRUS Bx Low Risk Prostate Cancer Important cancers are missed Jelle Barentsz Clinically insignificant cancers are identified by Prostate MR Center of Excellence
Prostate MRI for local staging and surgical planning in prostate cancer
Prostate MRI for local staging and surgical planning in prostate cancer 15th Annual Floyd A. Fried Advances in Urology Symposium June 23, 2017 Ray Tan, MD, MSHPM Assistant Professor Disclosures None Objectives
Optimal Imaging and Technical Aspects of Prostate SRT
Optimal Imaging and Technical Aspects of Prostate SRT Maris Mezeckis Dr., MBA, Vladislav Buryk Dr., PhD Sigulda Hospital Stereotactic Radiosurgery centre Homogeneous planning: PTV=prostate + 5 mm, 3 mm
Prostate Cancer Imaging :What the Urologist Needs to Know
Prostate Cancer Imaging :What the Urologist Needs to Know Poster No.: C-2513 Congress: ECR 2015 Type: Educational Exhibit Authors: C. Aimeur, M. tabouche, A. habouchi, A. Habba, B. Mansouri; Algiers/DZ
Multiparametric MRI diagnostic value in a case of prostate cancer
CASE REPORT J. Transl. Med. Res 2015;20(3):162-167 Multiparametric MRI diagnostic value in a case of prostate cancer Gelu Adrian Popa 1,4, Ioana Gabriela Lupescu 1,4, Emi M. Preda 1,4, Cristina Nicolae
My biopsy shows prostate cancer: How bad is it? How to stage prostate cancer
My biopsy shows prostate cancer: How bad is it? How to stage prostate cancer Giuseppe Petralia giuseppe.petralia@ieo.it Division of Radiology, IEO - European Institute of Oncology IRCCS, Milan Department
Structured MRI report in prostate cancer using the PIRADS criterias: the bridge between the imagist and the clinician
Structured MRI report in prostate cancer using the PIRADS criterias: the bridge between the imagist and the clinician Ioana G.Lupescu¹³, G.A.Popa¹³, G.Gluck²³, I.Sinescu²³ ¹ Radiology, Medical Imaging
Effect of intravenous contrast medium administration on prostate diffusion-weighted imaging
Effect of intravenous contrast medium administration on prostate diffusion-weighted imaging Poster No.: C-1766 Congress: ECR 2015 Type: Authors: Keywords: DOI: Scientific Exhibit J. Bae, C. K. Kim, S.
Multiparametric MR Imaging in Prostate Cancer Diagnosis: make it easy
Multiparametric MR Imaging in Prostate Cancer Diagnosis: make it easy Poster No.: C-1811 Congress: ECR 2015 Type: Educational Exhibit Authors: G. Popa, C. Scheau, A. preda, I. G. Lupescu; Bucharest/RO
The role of T2-weighted imaging in detecting prostate cancer of the central zone in 3T multiparametric magnetic resonance examination
The role of T2-weighted imaging in detecting prostate cancer of the central zone in 3T multiparametric magnetic resonance examination Poster No.: C-2317 Congress: ECR 2014 Type: Scientific Exhibit Authors:
JMSCR Vol 05 Issue 02 Page February 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i2.151 Research Article Role of Multiparametric
Essential Initial Activities and Clinical Outcomes
Essential Initial Activities and Clinical Outcomes Crystal Farrell 1,2 & Sabrina L. Noyes 2, Joe Joslin 2, Manish Varma 2,3, Andrew Moriarity 2,3, Christopher Buchach 2,3, Leena Mammen 2,3, Brian R. Lane
Magnetic Resonance Imaging of Prostate Cancer: Approach, Local Staging and Therapeutic Impact
Magnetic Resonance Imaging of Prostate Cancer: Approach, Local Staging and Therapeutic Impact Poster No.: C-2270 Congress: ECR 2014 Type: Educational Exhibit Authors: M. Palmeiro, N. V. V. B. Marques,
MRI and Fusion biopsies. K Sahadevan Consultant Urologist
MRI and Fusion biopsies K Sahadevan Consultant Urologist MRI in Prostate Cancer Diagnosis Traditionally used for staging purposes 70 to 90% accurate detection of extra capsular disease on MRI (cornud 2002)
Clinical Prostate Cancer Imaging
Clinical Prostate Cancer Imaging Steven C. Eberhardt, MD Professor and Vice Chair of Clinical Operations Chief of Abdominal and Oncology Radiology UNM Health Sciences Center UNM Comprehensive Cancer Center
Pitfalls in Interpreting mp-mri of the Prostate: A Pictorial Review with Pathologic Correlation
Insights Imaging (2015) 6:611 630 DOI 10.1007/s13244-015-0426-9 PICTORIAL REVIEW Pitfalls in Interpreting mp-mri of the Prostate: A Pictorial Review with Pathologic Correlation V. Panebianco 1 & F. Barchetti
Essentials of Clinical MR, 2 nd edition. 73. Urinary Bladder and Male Pelvis
73. Urinary Bladder and Male Pelvis Urinary bladder carcinoma is best locally staged with MRI. It is important however to note that a thickened wall (> 5 mm) is a non-specific finding seen in an underfilled
First Clinical Experiences with Simultaneous Multi-Slice Accelerated Diffusion-Weighted Imaging Throughout the Body
Clinical Oncological Imaging First Clinical Experiences with Simultaneous Multi-Slice Accelerated Diffusion-Weighted Imaging Throughout the Body Valentin Tissot, M.D. 1 ; Olivier Legeas, M.D. 1 ; Isabelle
Diffusion Weighted Imaging in Prostate Cancer
Diffusion Weighted Imaging in Prostate Cancer Disclosure Information Vikas Kundra, M.D, Ph.D. No financial relationships to disclose. Education Goals and Objectives To describe the utility of diffusion-weighted
BI-RADS Update. Martha B. Mainiero, MD, FACR, FSBI Brown University Rhode Island Hospital
BI-RADS Update Martha B. Mainiero, MD, FACR, FSBI Brown University Rhode Island Hospital No Disclosures BI-RADS History 1980s Quality Issues ACR Accreditation BI-RADS 1994 2003 4 th Edition MRI, US January
Multiparametric 3T MR imaging of the prostate - acquisition protocols and image evaluation
Multiparametric 3T MR imaging of the prostate - acquisition protocols and image evaluation Poster No.: C-2215 Congress: ECR 2014 Type: Educational Exhibit Authors: L. Andrade, C. B. Marques, L. Curvo-Semedo,
CASE-BASED PITFALLS AND LIMITATIONS OF PIRADS v2.0
CASE-BASED PITFALLS AND LIMITATIONS OF PIRADS v2.0 Antonio Luna, MD, PhD. Medical Director. Health Time. Jaén, Spain. Assistant professor of radiology. Case Western Reserve University. Cleveland, OH. Scientific
Leonard M. Glassman MD
BI-RADS The New BI-RADS Leonard M. Glassman MD FACR Former Chief of Breast Imaging American Institute for Radiologic Pathology Washington Radiology Associates, PC Breast Imaging Reporting and Data System
Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer
Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer RadioGraphics 2018; 38:437 449 Pritesh Patel, MD Melvy S. Mathew, MD Igor Trilisky, MD Aytekin Oto, MD, MBA Jeffrey S. Klein,
Department of Radiology, Addenbrooke s Hospital and the University of Cambridge,
PI-RADS v - What you need to know Tristan Barrett MD 1, Baris Turkbey, Peter L. Choyke. 1 Department of Radiology, Addenbrooke s Hospital and the University of Cambridge, Cambridge, CB 0QQ, UK Molecular
Prostate biopsy: MR imaging to the rescue
Prostate biopsy: MR imaging to the rescue Poster No.: C-1855 Congress: ECR 2014 Type: Educational Exhibit Authors: N. V. V. B. Marques 1, J. Ip 1, A. Loureiro 2, J. Niza 1, M. Palmeiro 2, Keywords: DOI:
Magnetic Resonance Imaging in the management of prostate cancer: What the Radiologists need to know?
Magnetic Resonance Imaging in the management of prostate cancer: What the Radiologists need to know? Poster No.: C-0889 Congress: ECR 2014 Type: Educational Exhibit Authors: S. S. Deshpande, N. Sable,
The current status of MRI in prostate cancer
CLINICAL The current status of MRI in prostate cancer Kesley Pedler, Yu Xuan Kitzing, Celi Varol, Mohan Arianayagam Background The diagnosis and treatment of prostate cancer is a controversial topic. Until
MR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
MRI XR, CT, NM. Principal Modality (2): Case Report # 2. Date accepted: 15 March 2013
Radiological Category: Musculoskeletal Principal Modality (1): Principal Modality (2): MRI XR, CT, NM Case Report # 2 Submitted by: Hannah Safia Elamir, D.O. Faculty reviewer: Naga R. Chinapuvvula, M.D.
ACRIN 6666 IM Additional Evaluation: Additional Views/Targeted US
Additional Evaluation: Additional Views/Targeted US For revised or corrected form check box and fax to 215-717-0936. Instructions: The form is completed based on recommendations (from ID form) for additional
Utility of Prostate MRI. John R. Leyendecker, MD
Utility of Prostate MRI John R. Leyendecker, MD Professor of Radiology and Urology Executive Vice Chair of Clinical Operations Section Head, Abdominal Imaging Wake Forest University School of Medicine;
Outline (1) Outline (2) Concepts in Prostate Pathology. Peculiarities of Prostate Cancer. Peculiarities of Prostate Cancer
Concepts in Prostate Pathology Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Outline (1) Peculiarities of prostate cancer Peculiarities of prostate needle biopsy Needle bx vs. TURP Prostate
The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA
Association of quantitative magnetic resonance imaging parameters with histological findings from MRI/ultrasound Seyed Saeid Dianat, MD, 1 H. Ballentine Carter, MD, 2 Edward M. Schaeffer, MD, 2 Ulrike
PI-RADS v2 for predicting prostate cancer Gleason score at final pathology after radical prostatectomy
PI-RADS v2 for predicting prostate cancer Gleason score at final pathology after radical prostatectomy Poster No.: C-2866 Congress: ECR 2017 Type: Scientific Exhibit Authors: E. Demozzi, G. Foti, L. Romano,
Anatomic Imaging of Prostate Cancer
Masoom Haider, MD, FRCP(C) Professor of Radiology, University of Toronto Clinician Scientist, Ontario Institute of Cancer Research Senior Scientist, Sunnybrook Research Institute Chief, Dept of Medical
2
1 2 3 4 5 6 7 The RTOG contouring recommendations state the femurs are to be contourned to the bottom of the ischial tuberosity. 8 This slide shows the hourglass configuration. It is only present in about
MRI BI-RADS: How to make it out?
MRI BI-RADS: How to make it out? Poster No.: C-1850 Congress: ECR 2016 Type: Educational Exhibit Authors: M. Ben Ammar, A. Ben Miled, O. Ghdes, S. Harguem, A. Gaja, N. Mnif; Tunis/TN Keywords: Breast,
AB MR Interpretation Overview
AB MR Interpretation Overview Goal of AB MR interpretation is to maintain high sensitivity and specificity In order to minimize false positives and short term follow ups, it is fundamental to focus only
Kidney Case 1 SURGICAL PATHOLOGY REPORT
Kidney Case 1 Surgical Pathology Report February 9, 2007 Clinical History: This 45 year old woman was found to have a left renal mass. CT urography with reconstruction revealed a 2 cm medial mass which
Detection, Screening and. Jelle Barentsz, Radboudumc, Nijmegen, NL
Detection, Screening and Staging with mpmri Jelle Barentsz, Radboudumc, Nijmegen, NL NO CONFLICT OF INTEREST Paradigm shift Past staging TRUS-GBx ERC, MRSI invasive Current detection agressive PCa mpmri-directed
Imaging in breast cancer. Mammography and Ultrasound Donya Farrokh.MD Radiologist Mashhad University of Medical Since
Imaging in breast cancer Mammography and Ultrasound Donya Farrokh.MD Radiologist Mashhad University of Medical Since A mammogram report is a key component of the breast cancer diagnostic process. A mammogram
Research Article Evaluation of the PI-RADS Scoring System for Classifying mpmri Findings in Men with Suspicion of Prostate Cancer
BioMed Research International Volume 2013, Article ID 252939, 9 pages http://dx.doi.org/10.1155/2013/252939 Research Article Evaluation of the PI-RADS Scoring System for Classifying mpmri Findings in Men
PLACE LABEL HERE BASELINE / PRE-TREATMENT. ACRIN 6657 Extension MRI Form: Baseline / Pre-Treatment MRI 1. o Unknown
T1 ACRIN 6657 Extension MRI Form: Baseline / Pre-Treatment MRI 1 If this is a revised or corrected form, please box. ACRIN Study 6657 No. Instructions: In accordance with the protocol, four MRI exams are
Stephen McManus, MD David Levi, MD
Stephen McManus, MD David Levi, MD Prostate MRI Indications INITIAL DETECTION, STAGING, RECURRENT TUMOR LOCALIZATION, RADIATION THERAPY PLANNING INITIAL DETECTION Clinically suspected prostate cancer before
Value of MRI in Characterizing Adnexal Masses
The Journal of Obstetrics and Gynecology of India (July August 2015) 65(4):259 266 DOI 10.1007/s13224-015-0730-9 PHOTO ESSAY Value of MRI in Characterizing Adnexal Masses Alpana Karnik 1 Raina Anil Tembey
HHS Public Access Author manuscript Proc SPIE Int Soc Opt Eng. Author manuscript; available in PMC 2017 June 12.
Classification of Clinical Significance of MRI Prostate Findings Using 3D Convolutional Neural Networks Alireza Mehrtash a,b, Alireza Sedghi c, Mohsen Ghafoorian a,d, Mehdi Taghipour a, Clare M. Tempany
Evolution of prostate MRI: from multiparametric standard to less-is-better and different-is better strategies
Girometti et al. European Radiology Experimental (2019) 3:5 https://doi.org/10.1186/s41747-019-0088-3 European Radiology Experimental NARRATIVE REVIEW Evolution of prostate MRI: from multiparametric standard
6th ESUR Teaching Course on Prostate MRI, Berlin 2016
6th ESUR Teaching Course on Prostate MRI, Berlin 2016 Friday, June 10, 2016 8:00 am Registration 8:45 am Welcome Address B. Hamm and H. Thoeny 9:00 10:20 am Session 1 "ABC of the Prostate and mp- MRI:
Using Task Group 137 to Prescribe and Report Dose. Vrinda Narayana. Department of Radiation Oncology University of Michigan. The
Using Task Group 137 to Prescribe and Report Dose Vrinda Narayana The Department of Radiation Oncology University of Michigan TG137 AAPM Recommendations on Dose Prescription and Reporting Methods for Permanent
Accurate Diagnosis and Treatment
A Remarkable Achievement Magnetic Resonance Imaging Accurate Diagnosis and Treatment a HandBook for patients and curious doctors Samuel Aronson, M.D. Franck Bladou, M.D. Contributor Armen Aprikian, M.D.
Aims and objectives. Methods and materials. Background
Updated Prostate Imaging Reporting and Data System (PI-RADS) 2.0 versus 1.0: detection accuracy of prostate clinically significant and insignificant cancer Poster No.: C-1203 Congress: ECR 2016 Type: Scientific
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
Transformation of the South West Prostate Cancer Diagnostic Pathway. 14 th May 2018
Transformation of the South West Prostate Cancer Diagnostic Pathway 14 th May 2018 Introduction by Mr Jonathon Miller Introduction National context Achieving World Class Cancer Outcomes: A Strategy for
Prostate Biopsy in 2017
Prostate Biopsy in 2017 Bob Djavan, MD, PhD Professor and Chairman, Department of Urology, Rudolfinerhaus Foundation Hospital,Vienna, Austria Director Vienna Urology foundation Board member Scientific
Disclosure. Acknowledgement. What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Rectal cancer imaging. None
What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Zhen Jane Wang, MD Assistant Professor in Residence UC SF Department of Radiology Disclosure None Acknowledgement Hueylan Chern, MD, Department
Normal MR anatomy of the prostate gland
Normal MR anatomy of the prostate gland Poster No.: C-2173 Congress: ECR 2017 Type: Educational Exhibit Authors: K. Sklinda, M. Fr#czek, B. Mruk, J. Walecki; Warsaw/PL Keywords: Urinary Tract / Bladder,
PLACE LABEL HERE. ACRIN 6657 MRI Form: Pre-Treatment (MRI-1)
M3 ACRIN 6657 MRI Form: Pre-Treatment (MRI-1) If this is a revised or corrected form,indicate by checking box. ACRIN Study 6657 Case # Instructions: In accordance with the protocol, four MRI exams are
Alexander S. Somwaru 1*, Deepu Alex 2 and Atif Zaheer 3
Somwaru et al. BMC Medical Imaging (2016) 16:16 DOI 10.1186/s12880-016-0122-3 CASE REPORT Open Access Prostate cancer arising in ectopic prostatic tissue within the left seminal vesicle: a rare case diagnosed
Radiologic and pathologic correlation of non-mass like breast lesions on US and MRI: Benign, high risk, versus malignant
Radiologic and pathologic correlation of non-mass like breast lesions on US and MRI: Benign, high risk, versus malignant Poster No.: C-1161 Congress: ECR 2013 Type: Educational Exhibit Authors: J. Kwak,
Radiologic and pathologic correlation of non-mass like breast lesions on US and MRI: Benign, high risk, versus malignant
Radiologic and pathologic correlation of non-mass like breast lesions on US and MRI: Benign, high risk, versus malignant Poster No.: C-1161 Congress: ECR 2013 Type: Educational Exhibit Authors: J. Kwak,
PI-RADS classification: prognostic value for prostate cancer grading
PI-RADS classification: prognostic value for prostate cancer grading Poster No.: C-1622 Congress: ECR 2014 Type: Scientific Exhibit Authors: I. Platzek, A. Borkowetz, T. Paulus, T. Brauer, M. Wirth, M.
Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.
Case Scenario 1 3/8/13 H&P 68 YR W/M presents w/elevated PSA. Patient is a non-smoker, current alcohol use. Physical Exam: On digital rectal exam the sphincter tone is normal and there is a 1 cm nodule
Pieter De Visschere, Eva Pattyn, Piet Ost, Tom Claeys, Nicolaas Lumen and Geert Villeirs
De Visschere, P et al 2016 Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and 2. Journal of the Belgian Society of Radiology, 100(1): 108, pp. 1 10, DOI: http://dx.doi.org/10.5334/jbr-btr.1147
Prostate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
Breast Imaging Lexicon
9//201 200 BI RADS th Edition 201 BI RADS th Edition Breast Imaging Lexicon Mammographic Pathology and Assessment Categories Deborah Thames, R.T.(R)(M)(QM) The Advanced Health Education Center Nonmember:
New research in prostate brachytherapy
New research in prostate brachytherapy Dr Ann Henry Associate Professor in Clinical Oncology University of Leeds and Leeds Cancer Centre PIVOTAL boost opening 2017 To evaluate - The benefits of pelvic
Brief History. Identification : Past History : HTN without regular treatment.
Brief History Identification : Name : 陳 x - Admission : 94/10/06 Gender : male Age : 75 y/o Chief Complaint : Urinary difficulty for months. Past History : HTN without regular treatment. Brief History
Ectopic Prostatic Tissue in the Rectum: A Case Report 직장에발생된이소성전립선조직 : 증례보고
Case Report pissn 1738-2637 / eissn 2288-2928 https://doi.org/10.3348/jksr.2017.76.2.91 Ectopic Prostatic Tissue in the Rectum: A Case Report 직장에발생된이소성전립선조직 : 증례보고 Myung Jin Seol, MD 1, Kyung Hee Noh,
Advancements in MR Imaging of the Prostate: From Diagnosis to Interventions 1
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. GENITOURINARY IMAGING
Genitourinary Imaging Original Research
Genitourinary Imaging Original Research Felker et al. PI-RADSv2 Category 3 TZ Lesions Genitourinary Imaging Original Research Ely R. Felker 1 Steven S. Raman 1 Daniel J. Margolis 2 David S. K. Lu 1 Nicholas
Prostate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018
Prostate cancer staging and datasets: The Nitty-Gritty What determines our pathological reports? Dan Berney Maastricht 2018 Biopsy reporting. How not to do it. The TNM 8 th edition. Changes good and bad
Index Lesion Only. Prof. Phillip D Stricker
Index Lesion Only Prof. Phillip D Stricker Financial and Other Disclosures Off-label use of drugs, devices, or other agents: None Data from IRB-approved human research is presented I have the following
Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer
1 di 13 25/05/2016 10.10 J Clin Imaging Sci. 2016; 6: 18. Published online 2016 Apr 29. doi: 10.4103/2156-7514.181494 PMCID: PMC4863405 Multiparametric Magnetic Resonance Imaging of Recurrent Prostate